vs
Side-by-side financial comparison of Apyx Medical Corp (APYX) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
Sight Sciences, Inc. is the larger business by last-quarter revenue ($20.4M vs $19.2M, roughly 1.1× Apyx Medical Corp). Apyx Medical Corp runs the higher net margin — -6.8% vs -20.4%, a 13.6% gap on every dollar of revenue. On growth, Apyx Medical Corp posted the faster year-over-year revenue change (34.7% vs 6.9%). Sight Sciences, Inc. produced more free cash flow last quarter ($-2.0M vs $-2.8M). Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 2.9%).
Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
APYX vs SGHT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $20.4M |
| Net Profit | $-1.3M | $-4.2M |
| Gross Margin | 62.6% | 87.3% |
| Operating Margin | 0.1% | -18.0% |
| Net Margin | -6.8% | -20.4% |
| Revenue YoY | 34.7% | 6.9% |
| Net Profit YoY | 71.9% | 64.9% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $20.4M | ||
| Q3 25 | $12.9M | $19.9M | ||
| Q2 25 | $11.4M | $19.6M | ||
| Q1 25 | $9.4M | $17.5M | ||
| Q4 24 | $14.2M | $19.1M | ||
| Q3 24 | $11.5M | $20.2M | ||
| Q2 24 | $12.1M | $21.4M | ||
| Q1 24 | $10.2M | $19.3M |
| Q4 25 | $-1.3M | $-4.2M | ||
| Q3 25 | $-2.0M | $-8.2M | ||
| Q2 25 | $-3.8M | $-11.9M | ||
| Q1 25 | $-4.2M | $-14.2M | ||
| Q4 24 | $-4.6M | $-11.8M | ||
| Q3 24 | $-4.7M | $-11.1M | ||
| Q2 24 | $-6.6M | $-12.3M | ||
| Q1 24 | $-7.6M | $-16.3M |
| Q4 25 | 62.6% | 87.3% | ||
| Q3 25 | 64.4% | 86.4% | ||
| Q2 25 | 62.3% | 84.8% | ||
| Q1 25 | 60.1% | 86.2% | ||
| Q4 24 | 63.0% | 86.8% | ||
| Q3 24 | 60.5% | 83.9% | ||
| Q2 24 | 61.7% | 85.8% | ||
| Q1 24 | 58.1% | 85.5% |
| Q4 25 | 0.1% | -18.0% | ||
| Q3 25 | -6.5% | -39.7% | ||
| Q2 25 | -22.6% | -59.6% | ||
| Q1 25 | -32.4% | -79.2% | ||
| Q4 24 | -21.4% | -62.5% | ||
| Q3 24 | -31.6% | -55.7% | ||
| Q2 24 | -45.7% | -59.2% | ||
| Q1 24 | -64.6% | -76.4% |
| Q4 25 | -6.8% | -20.4% | ||
| Q3 25 | -15.4% | -41.0% | ||
| Q2 25 | -33.2% | -61.0% | ||
| Q1 25 | -44.0% | -80.8% | ||
| Q4 24 | -32.5% | -62.1% | ||
| Q3 24 | -40.9% | -54.9% | ||
| Q2 24 | -54.0% | -57.7% | ||
| Q1 24 | -74.0% | -84.4% |
| Q4 25 | — | $-0.07 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | — | $-0.23 | ||
| Q1 25 | — | $-0.28 | ||
| Q4 24 | — | $-0.23 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | $-0.19 | $-0.25 | ||
| Q1 24 | $-0.22 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | $92.0M |
| Total DebtLower is stronger | $37.5M | $42.4M |
| Stockholders' EquityBook value | $14.5M | $63.9M |
| Total Assets | $66.8M | $115.3M |
| Debt / EquityLower = less leverage | 2.58× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.7M | $92.0M | ||
| Q3 25 | $25.1M | $92.4M | ||
| Q2 25 | $29.3M | $101.5M | ||
| Q1 25 | $31.0M | $108.8M | ||
| Q4 24 | $31.7M | $120.4M | ||
| Q3 24 | $28.0M | $118.6M | ||
| Q2 24 | $32.7M | $118.2M | ||
| Q1 24 | $37.3M | $127.3M |
| Q4 25 | $37.5M | $42.4M | ||
| Q3 25 | $37.5M | $42.4M | ||
| Q2 25 | $37.5M | $42.4M | ||
| Q1 25 | $37.5M | $42.4M | ||
| Q4 24 | $37.5M | $40.0M | ||
| Q3 24 | $37.5M | $37.1M | ||
| Q2 24 | — | $35.0M | ||
| Q1 24 | — | $35.0M |
| Q4 25 | $14.5M | $63.9M | ||
| Q3 25 | $5.8M | $64.3M | ||
| Q2 25 | $7.3M | $70.0M | ||
| Q1 25 | $10.5M | $77.6M | ||
| Q4 24 | $14.2M | $87.5M | ||
| Q3 24 | $11.0M | $95.0M | ||
| Q2 24 | $14.7M | $101.6M | ||
| Q1 24 | $20.3M | $109.2M |
| Q4 25 | $66.8M | $115.3M | ||
| Q3 25 | $57.4M | $116.3M | ||
| Q2 25 | $58.2M | $122.0M | ||
| Q1 25 | $60.2M | $129.7M | ||
| Q4 24 | $64.8M | $142.8M | ||
| Q3 24 | $60.7M | $143.6M | ||
| Q2 24 | $65.4M | $149.7M | ||
| Q1 24 | $70.7M | $155.6M |
| Q4 25 | 2.58× | 0.66× | ||
| Q3 25 | 6.41× | 0.66× | ||
| Q2 25 | 5.17× | 0.61× | ||
| Q1 25 | 3.57× | 0.55× | ||
| Q4 24 | 2.64× | 0.46× | ||
| Q3 24 | 3.40× | 0.39× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.32× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.5M | $-1.8M |
| Free Cash FlowOCF − Capex | $-2.8M | $-2.0M |
| FCF MarginFCF / Revenue | -14.6% | -9.7% |
| Capex IntensityCapex / Revenue | 1.4% | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.5M | $-1.8M | ||
| Q3 25 | $-3.5M | $-8.7M | ||
| Q2 25 | $-1.2M | $-7.5M | ||
| Q1 25 | $-702.0K | $-11.6M | ||
| Q4 24 | $-2.9M | $-3.5M | ||
| Q3 24 | $-4.4M | $362.0K | ||
| Q2 24 | $-4.3M | $-9.5M | ||
| Q1 24 | $-6.3M | $-9.8M |
| Q4 25 | $-2.8M | $-2.0M | ||
| Q3 25 | $-4.1M | $-8.9M | ||
| Q2 25 | $-1.5M | $-7.8M | ||
| Q1 25 | $-757.0K | — | ||
| Q4 24 | $-3.2M | $-3.6M | ||
| Q3 24 | $-4.6M | $311.0K | ||
| Q2 24 | $-4.6M | $-9.5M | ||
| Q1 24 | $-6.4M | $-9.9M |
| Q4 25 | -14.6% | -9.7% | ||
| Q3 25 | -31.5% | -44.7% | ||
| Q2 25 | -13.2% | -39.6% | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | -22.4% | -18.9% | ||
| Q3 24 | -40.0% | 1.5% | ||
| Q2 24 | -38.0% | -44.7% | ||
| Q1 24 | -62.2% | -51.4% |
| Q4 25 | 1.4% | 0.8% | ||
| Q3 25 | 4.0% | 0.9% | ||
| Q2 25 | 2.3% | 1.1% | ||
| Q1 25 | 0.6% | 0.0% | ||
| Q4 24 | 1.7% | 0.7% | ||
| Q3 24 | 1.3% | 0.3% | ||
| Q2 24 | 2.4% | 0.4% | ||
| Q1 24 | 0.3% | 0.6% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APYX
Segment breakdown not available.
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
